In November 2025, Traphaco celebrates its 53rd anniversary of establishment and development with the message “Always striving for Vietnamese health,” affirming its journey of over half a century dedicated to serving the community through quality, science, and continuous innovation. From a small production unit under the railway sector in 1972, Traphaco has grown into a leading pharmaceutical company in Vietnam, pioneering the development of a standardized herbal medicine value chain—modern technology—and dedicated human resources.
Amid the war years, Traphaco was founded with the mission of producing medicines to serve the North-South railway line. During the renovation period, with strategic vision and pioneering spirit, Traphaco became the first enterprise to modernize Vietnamese traditional medicine, opening a unique path—combining traditional medical knowledge with modern technology.
Traphaco Achieves Vietnam Record
Since 2009, Traphaco has implemented the GreenPlan Project—Research and Sustainable Development of Vietnamese Herbal Resources, establishing the “4-House” model (State—Scientists—Farmers—Enterprises), closely linking production and community livelihoods. To date, the company has developed 10 GACP-WHO-certified herbal regions in Lao Cai, Nam Dinh (former), Phu Tho, Phu Yen (former), etc., with over 880 households participating in cultivating and harvesting standardized herbal materials, and thousands of hectares of herbal materials controlled according to GACP-WHO guidelines. Each cultivation area is not only a source of high-quality raw materials but also a sustainable poverty alleviation model, helping locals achieve stable incomes several times higher than rice and corn cultivation, contributing to land and forest preservation and the conservation of local ecosystems.
According to WHO’s GACP standards, every process from seed selection, cultivation, irrigation, harvesting, storage to transportation of herbal materials is strictly controlled to ensure a safe, clean input source, free from chemical residues, and with the highest active ingredient content. Traphaco is the first enterprise in Vietnam to build a large-scale GACP-WHO-certified cultivation chain, becoming a model for the Vietnamese pharmaceutical industry in terms of quality from the source—full transparency.
Entering the integration phase, Traphaco has defined a dual development strategy: Premium Traditional Medicine—High-Quality Modern Medicine. Familiar brands like Boganic, Hoat Huyet Duong Nao, Tottri, and Cebraton continue to assert their leading market position, while Boganic Premium and Cebraton Premium open a new era for premium traditional medicine products.
In the field of modern medicine, Traphaco has implemented a strategic cooperation with Daewoong Group (South Korea)—one of the top three pharmaceutical companies in South Korea—to transfer technology and enhance high-quality drug production capacity. From 2021 to now, the project has entered phase 2 with about 20 transferred products, out of a total of 8 phases and 70 key products in the program. In parallel, Traphaco actively promotes the research and development of bioequivalent drugs (BE) and first generics to meet the increasing treatment needs of Vietnamese patients. This cooperation not only shortens the research and development process but also enhances technical capabilities, opening up opportunities to export “Made in Vietnam” drugs to the region.
Traphaco Confident in the Strong Competitiveness of Its Two Strategic Product Lines
In 2025, Traphaco executed a dual movement: restructuring the distribution system and comprehensive digital transformation. The company streamlined its branch model, established a National Order Center and a specialized logistics company, and integrated artificial intelligence (AI) into core activities: herbal material testing, accounting, supply chain, customer care, and marketing. The AI system for raw material quality management allows traceability of each batch of herbal materials from cultivation to finished products, enhancing control capabilities and operational efficiency.
According to the 9-month report of 2025, Traphaco’s revenue increased by 8.5%, and profit rose by 8% compared to the same period in 2024. The two strategic product groups—Premium Traditional Medicine and High-Quality Modern Medicine—grew by 65% and 55%, respectively, becoming the company’s key drivers. Traphaco has developed 12 bioequivalent drugs and aims for 17 products by year-end, helping Vietnamese patients access high-quality medicines at reasonable costs.
Bioequivalent Drugs (BE) Are Traphaco’s Spearhead in High-Quality Modern Medicine
Throughout its development and brand affirmation journey, the company has consistently maintained the title of “National Brand,” honored in the Top 10 Sustainable Enterprises CSI, Top 50 Best Listed Companies in Vietnam (Forbes), Excellent and Sustainable Asian Enterprise, and Top 10 Golden Star of Vietnam for many years. Key products like Boganic, Hoat Huyet Duong Nao, Tottri, and Cebraton consistently achieve record consumption, maintaining top market share in Vietnam’s traditional medicine market.
On November 21, 2025, Traphaco held the Handover Ceremony of the CEO position, marking a significant shift in governance. The new CEO, Ms. Dao Thuy Ha, believes that in the context of the country’s transformation towards more transparent management, Traphaco has many opportunities to break through strongly, maintain its pioneering spirit of innovation, accelerate the EU-GMP standard factory project, maintain its leading position in traditional medicine, and accelerate in modern medicine, strongly applying digital transformation and AI in management and supply chains, investing in product innovation to adapt to modern healthcare needs.
The message “Traphaco 53 Years of Always Striving for Vietnamese Health” is not only a tribute to millions of consumers who have accompanied the company but also a commitment from Traphaco on its new journey—bringing Vietnamese intelligence, resilience, and dedication to the forefront in the field of high-tech pharmaceuticals.
Government and Prime Minister’s Directives and Operations on November 23, 2025
The Government Office has issued a press release outlining the directives and instructions from the Government and the Prime Minister as of November 23, 2025.
Unifying the Expansion Plan for Phase 2 of the Nghi Son Refinery
The Prime Minister has tasked the National Industry-Energy Corporation with collaborating alongside Nghi Son Refinery and Petrochemical LLC and its investors to finalize the expansion plan for Phase 2 of the Nghi Son Refinery and Petrochemical Complex.
Former Traphaco CEO Reveals Reasons for Resignation Before Term Completion
“When I announced my decision during the meeting, most people were taken aback, asking, ‘Why now?’—Mr. Trần Túc Mã remarked.”
Unveiling the Financial and Banking Industry’s Rising Stars of 2025
In a year marked by significant shifts in the banking sector, the distinguishing factor among financial institutions lies in their strategic choices, risk management approaches, and ability to capitalize on growth opportunities. From the leadership demonstrated by major banks to the remarkable advancements of dynamic players, the market has witnessed several notable highlights.
Vietnamese and South African Businesses: Prime Minister Urges ‘Meet, Connect, Act, Deliver’
On the morning of November 21st (local time, afternoon in Hanoi), Prime Minister Pham Minh Chinh attended the Vietnam-South Africa Business Forum in Johannesburg. This engagement coincided with his participation in the 2025 G20 Summit and bilateral meetings in South Africa.
